(Total Views: 204)
Posted On: 07/02/2019 2:48:12 PM
Post# of 36566
Re: OrlandoJohn #4485
Maybe we'll be even luckier than Kite. Kite had just CAR-T, where we have AE37, CAR-T, plus 3 other technolgies that Kiromic has.
CAR-T seems to require a huge investment of lab space to actually process patient's blood and produce the re-engineered T-cells to give back to the patient. Gilead bought Kite and is now building the facility.
So, the new NGIO could easily be an acquisition target for a big pharma wanting to get into the hottest thing - CAR-T.
CAR-T seems to require a huge investment of lab space to actually process patient's blood and produce the re-engineered T-cells to give back to the patient. Gilead bought Kite and is now building the facility.
So, the new NGIO could easily be an acquisition target for a big pharma wanting to get into the hottest thing - CAR-T.
(0)
(0)
